Talquetamab Multiple Myeloma: Impact, Evidence,...

By Staff Writer

July 9, 2025

Talquetamab multiple myeloma is an emerging treatment option for adults with relapsed and refractory multiple myeloma (RRMM) who have progressed after at least three prior therapies. For patients facing limited options, how does talquetamab (marke...
Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study
BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhi...
AI Clinician in Pediatric ICU: A Review and HEOR Perspective
Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential
FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...
NICE Rejects Donanemab: Treatment Cost-Effectiveness
Efficacy of Ultomiris Pediatric TMA Treatment
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implic...